GBA Presents: THE GREEN MARKET

Alert- NRx Pharma files for FDA’s Breakthrough Therapy Designation for COVID-19 therapy
Dec. 29, 2021 7:12 AM ETNRx Pharmaceuticals, Inc. (NRXP)
medium_image_1215406880.jpg



  • NRx Pharmaceuticals (NASDAQ:NRXP) has added ~13.3% in the pre-market after announcing that the company filed a new Breakthrough Therapy Designation (BTD) request with the FDA for its experimental COVID-19 therapy ZYESAMI (aviptadil).
  • The BTD request focuses on critically ill COVID-19 patients with respiratory failure, who are at immediate risk of death despite the treatments with remdesivir and other approved therapies.
  • The filing was in response to a request made by the regulator for clinical data comparing ZYESAMI with Gilead’s (NASDAQ:GILD) antiviral therapy for COVID-19, Remdesivir.
  • According to the company, the patients who received ZYESAMI after Remdesivir have shown a statistically significant (P=0.03) 2.8-fold increased odds of being both alive and free of respiratory failure compared to placebo at both 28 and 60 days.
  • Meanwhile, 70% of those who received Remdesivir and progressed on the disease even after all approved therapies, ZYESAMI has led to a “highly significant” fourfold increased odds of survival compared to placebo at Day 60 (P=.006).
 
Keeping in mind that critical patients is a smaller subset...
NRXP MIGHT BE WORTH A GUMMY STOCK WAS $40 IN JUNE.

NRXP @ $5 gummy of the day

5.000.50 (+11.11%)9:31 AM 12/29/21
 
Itron named 'contrarian, beaten-down' clean tech idea at Raymond James 06:21 ITRI Raymond James analyst Pavel Molchanov calls Itron a "contrarian, beaten-down" clean technology investment idea for 2022. Power grid modernization is a theme to which Itron is "uniquely leveraged among U.S.-listed companies," Molchanov tells investors in a research note. This is a "very far from a crowded trade" as the supply chain issues that hit the stock in August erased its earlier outperformance for the year, says the analyst. Meanwhile, the supply chain headwinds of 2021 are starting to dissipate, "heralding a back-end weighted revenue recovery in 2022," contends Molchanov. He believes the U.S. and European infrastructure initiatives "provide structural tailwinds" and notes Itron has "plenty of dry powder" for acquisitions in software. Molchanov reiterates a Strong Buy rating on the shares with a $98 price target.

I like Itron from the old days. Lets look into this. Used to do water meters.
 
Dr. Calvin Sun, an emergency physician in New York City, described the unprecedented strain that hospitals are currently experiencing nationwide.

"We're trying to make ends meet, we're increasing premium pay, we're closing out three of our urgent care centers in Manhattan - at least 15 in New York City - this is the life of a per diem doctor, everywhere," Sun told Yahoo Finance on Wednesday.

"On top of that, we're frontline doctors, we've been working two years straight and there's no end in sight," Sun added, addressing severe levels of burnout that have been reported by health care workers.
 
$161--->$165 since we began following Louie V-- I think this may be my 3rd stock for 2022.

LVMH Moët Hennessy - Louis Vuitton, Société Européenne (LVMUY)

165.24-0.26(-0.15%)
 
The AZEK Company Inc. (AZEK)-- for all the great housing numbers we are not really up that much here! >I'm surprised This is still buyable folks
NYSE - Nasdaq Real Time Price. Currency in USD

45.78+0.06(+0.14%)
 
You must log in or register to reply here.
Back
Top